Isofol Medical: AGENT phase III trial fails - DNB

Isofol Medical announced that the phase III trial AGENT had failed to reach its primary and most important secondary endpoints. This is a huge disappointment and reduces the company’s valuation significantly (as arfolitixorin – the drug evaluated in the AGENT trial – was its only asset in clinical development). We have cut our fair value to SEK0–3 (14–26).

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_198410.pdf